Journal
EUROPEAN THYROID JOURNAL
Volume 12, Issue 3, Pages -Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ETJ-22-0227
Keywords
advanced follicular thyroid carcinoma; GEMOX (gemcitabine plus oxaliplatin); multikinase inhibitors
Categories
Ask authors/readers for more resources
This case report highlights the potential efficacy of GEMOX chemotherapy in patients with advanced follicular thyroid carcinoma resistant to multikinase inhibitors. The durable response to GEMOX significantly extended the overall survival of the patient.
Background: Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinomas represent the vast majority of cases. However, it should be noted that MKI have a non-negligible toxicity that may decrease the patient's quality of life. Conventional chemotherapy with GEMOX (gemcitabine plus oxaliplatin) is an off-label therapy, which seems to have some effectiveness in advanced differentiated thyroid carcinomas, with a good safety profile, although further studies are needed. Case report: We report a case of a metastatic FTC, resistant to several lines of therapy. However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy.Conclusion: GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available